|
|
|
|
|
|
Sponsors and Collaborators: |
M.D. Anderson Cancer Center Aventis Pharmaceuticals |
Information provided by: | M.D. Anderson Cancer Center |
ClinicalTrials.gov Identifier: | NCT00527761 |
Primary Objective:
1. To determine the maximum tolerated dose of chemotherapy using Taxotere, Temodar, Cisplatin (TTC) in patients with metastatic melanoma.
Secondary Objectives:
Condition | Intervention | Phase |
Metastatic Melanoma |
Drug: Cisplatin Drug: Taxotere Drug: Temodar |
Phase I |
MedlinePlus related topics: | Cancer Melanoma |
ChemIDplus related topics: | Cisplatin Docetaxel Temozolomide |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Phase I Study of TTC (Taxotere/Temodar/Cisplatin) in Metastatic Melanoma Patients |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Texas | |||||
U.T.M.D. Anderson Cancer Center | |||||
Houston, Texas, United States, 77030 |
M.D. Anderson Cancer Center |
Aventis Pharmaceuticals |
Principal Investigator: | Kevin B. Kim, MD | U.T.M.D. Anderson Cancer Center |
Study ID Numbers: | 2003-1037 |
First Received: | September 10, 2007 |
Last Updated: | October 15, 2007 |
ClinicalTrials.gov Identifier: | NCT00527761 |
Health Authority: | United States: Institutional Review Board |
|
|
|
|
|
|